Document:

Your Internet Defender, Inc. 8-K/A 

Exhibit 10.23

 

THIS WARRANT, AND THE SECURITIES ISSUABLE UPON THE EXERCISE OF THIS WARRANT, HAVE NOT
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAWS. THEY MAY NOT
BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN
OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNSEL) REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED
UNDER THE ACT, OR ANY APPLICABLE STATE SECURITIES LAWS.

 

WARRANT AGREEMENT

 

To Purchase Shares of Common Stock of

 

CORINDUS VASCULAR ROBOTICS, INC.

 

Dated as of August 12, 2014 (the “Effective Date”)

 

WHEREAS, CORINDUS, INC., a Delaware corporation (the “Predecessor Company”),
entered into a Loan and Security Agreement dated as of June 11, 2014 (the “Loan Agreement”) with STEWARD CAPITAL
HOLDINGS, LP, a Delaware limited partnership (the “Warrantholder”);

 

WHEREAS, the Predecessor Company issued to Warrantholder that certain Warrant to Purchase
Shares of Preferred Stock of the Company, dated June 11, 2014 (the “Prior Warrant”);

 

WHEREAS, the Predecessor Company and the Company entered into a Securities Exchange and
Acquisition Agreement dated August 5, 2014 whereby the Company agreed to acquire 100% of the issued and outstanding shares of
common stock and preferred stock of the Predecessor Company and rights to acquire shares of common stock and preferred stock of
the Predecessor Company, including the Prior Warrant, through an acquisition in exchange for the issuance of shares and rights
to acquire shares of the Company’s Common Stock; and

 

WHEREAS, the Company and the Warrantholder desire to amend and restate the Prior Warrant
as set forth in this Warrant Agreement (the “Agreement”) to reflect the right to purchase shares of Common
Stock of the Company.

 

NOW, THEREFORE, the parties hereby agree as follows:

 

SECTION
1.

 

GRANT OF THE RIGHT TO
PURCHASE COMMON STOCK

 

For value received, the Company hereby grants to the Warrantholder, and the Warrantholder
is entitled, upon the terms and subject to the conditions hereinafter set forth, to subscribe for and purchase, from the Company,
an aggregate number of fully paid and non-assessable shares of Common Stock equal to the quotient derived by dividing (a) the
Warrant Coverage (as defined below) by (b) the Exercise Price (defined below). The Exercise Price of such shares is subject
to adjustment as provided in Section 8. This Agreement is issued in substitution of and replacement for the Prior Warrant. As
used herein, the following terms shall have the following meanings:

 

    	 

    	 

    

 

“Act” means the Securities Act of 1933, as amended;

 

“Company” means Corindus Vascular Robotics, Inc., a Delaware corporation,
and any successor or surviving entity that assumes the obligations of the Company under this Agreement pursuant to Section 8(a);

 

“Charter” means the Company’s Articles of Incorporation, Certificate
of Incorporation or other constitutional document, as may be amended from time to time;

 

“Common Stock” means the Company’s common stock, $0.0001 par
value per share;

 

“Exercise Price” means $1.4083 per share, subject to adjustment pursuant
to Section 8;

 

“Initial Public Offering” means the initial underwritten
public offering of the Company’s Common Stock pursuant to a registration statement under the Act, which public offering
has been declared effective by the Securities and Exchange Commission (“SEC”);

 

“Merger Event” means any sale, lease or other transfer of all or substantially
all assets of the Company or any merger or consolidation involving the Company in which the Company or an affiliate is not the
surviving entity, or in which the outstanding shares of the Company’s capital stock are otherwise converted into or exchanged
for shares of preferred stock, other securities or property of another entity that is not an affiliate of the Company;

 

“Purchase Price” means, with respect to any exercise of this Agreement,
an amount equal to the Exercise Price as of the relevant time multiplied by the number of shares of Common Stock requested to
be exercised under this Agreement pursuant to such exercise.

 

“Warrant Coverage” means either (a) $250,000 if Company draws only
Tranche A under the Loan Agreement, or (b) $500,000 if Company draws both Tranche A and Tranche B under the Loan Agreement (as
“Tranche A” and “Tranche B” are each defined under the Loan Agreement).

 

SECTION
2.

 

TERM OF THE AGREEMENT

 

Except as otherwise provided for herein, the term of this Agreement and the right to
purchase Common Stock as granted herein (the “Warrant) shall commence on the Effective Date and shall be exercisable for
a period ending upon the earlier to occur of (i) June 11, 2024; or (ii) five (5) years after the Initial Public Offering.

 

    	- 2 -

    	 

    

 

SECTION
3.

 

EXERCISE OF THE PURCHASE
RIGHTS

 

(a)          Exercise. The purchase
rights set forth in this Agreement are exercisable by the Warrantholder, in whole or in part, at any time, or from time to time,
prior to the expiration of the term set forth in Section 2, by tendering to the Company at its principal office a notice of exercise
in the form attached hereto as Exhibit I (the “Notice of Exercise”), duly completed and executed. Promptly
upon receipt of the Notice of Exercise and the payment of the Purchase Price in accordance with the terms set forth below, and
in no event later than three (3) days thereafter, the Company shall issue to the Warrantholder a certificate for the number of
shares of Common Stock purchased and shall execute the acknowledgment of exercise in the form attached hereto as Exhibit II
(the “Acknowledgment of Exercise”) indicating the number of shares which remain subject to future purchases,
if any.

 

The Purchase Price may be paid at the Warrantholder’s election either (i) by cash
or check, or (ii) by surrender of all or a portion of the Warrant for shares of Common Stock to be exercised under this Agreement
and, if applicable, an amended Agreement representing the remaining number of shares purchasable hereunder, as determined below
(“Net Issuance”). If the Warrantholder elects the Net Issuance method, the Company will issue Common Stock
in accordance with the following formula:

 

	X= 	Y(A-B)

  A	 

 

Where:

 

	 	X =	the number of shares of Common Stock to be issued to the Warrantholder.
	 	 	 
	 	Y =	the number of shares of Common Stock requested to be exercised under this Agreement.
	 	 	 
	 	A =	the fair market value of one (1) share of Common Stock at the time of issuance of such shares of Common Stock,
	 	 	 
	 	B =	the Exercise Price.

 

For purposes of the above calculation, current fair market value of Common Stock shall
mean with respect to each share of Common Stock:

 

(i)           if the
exercise is in connection with an Initial Public Offering, and if the Company’s Registration Statement relating to such
Initial Public Offering has been declared effective by the SEC, then the fair market value per share shall be the initial “Price
to Public” of the Common Stock specified in the final prospectus with respect to the offering;

 

    	- 3 -

    	 

    

 

(ii)          if the exercise
is after, and not in connection with an Initial Public Offering, or if the Common Stock is otherwise traded on a securities exchange
or over-the-counter and not in connection with an Initial Public Offering, and:

 

(A)          if the Common
Stock is traded on a securities exchange, the fair market value shall be deemed to be the average of the closing prices over a
five (5) day period ending three days before the day the current fair market value of the securities is being determined; or

 

(B)          if the Common
Stock is traded over-the-counter, the fair market value shall be deemed to be the average of the closing bid and asked prices
quoted on the NASDAQ system (or similar system) over the five (5) day period ending three days before the day the current fair
market value of the securities is being determined;

 

(iii)         if at any time the
Common Stock is not listed on any securities exchange or quoted in the NASDAQ National Market or the over-the-counter market,
the current fair market value of Common Stock shall be the price per share most recently determined by the Board of Directors
of the Company to represent such fair market value per share, as determined in good faith by its Board of Directors (provided,
that if the Board of Directors has not made such a determination within the six-month period prior to the date of exercise, then
the Board of Directors shall provide, or cause to be provided to, the Warrantholder notice of a determination of such fair market
value per share within 15 days after the date of exercise), unless the Company shall become subject to a Merger Event, in which
case the fair market value of Common Stock shall be deemed to be the per share value received by the holders of the Company’s
Common Stock pursuant to such Merger Event.

 

Upon partial exercise by either cash or Net Issuance, the Company shall promptly issue
an amended Agreement representing the remaining number of shares purchasable hereunder. All other terms and conditions of such
amended Agreement shall be identical to those contained herein, including, but not limited to the Effective Date hereof.

 

(b)          Exercise Prior to Expiration.
To the extent this Agreement is not previously exercised as to all Common Stock subject hereto, and if the fair market value of
one share of the Common Stock is greater than the Exercise Price then in effect, this Agreement shall be deemed automatically
exercised pursuant to Section 3(a) (even if not surrendered) immediately before its expiration, the consideration for which shall
be, at the Warrantholder’s election, upon written notice to the Warrantholder, (i) by cash or check or (ii) Net Issuance.
For purposes of such automatic exercise, the fair market value of one share of the Common Stock upon such expiration shall be
determined pursuant to Section 3(a). To the extent this Agreement or any portion thereof is deemed automatically exercised pursuant
to this Section 3(b), the Company agrees to promptly notify the Warrantholder of the number of shares of Common Stock, if any,
the Warrantholder is to receive by reason of such automatic exercise.

 

    	- 4 -

    	 

    

 

(c)          Exercise Date.
Each exercise of this Agreement shall be deemed to have been effected immediately prior to the close of business on the day on
which this Agreement shall have been surrendered to the Company as provided in subsection (a) above.

 

SECTION
4.

 

RESERVATION OF SHARES

 

During the term of this Agreement the Company will at all times have authorized and reserved
a sufficient number of shares of its Common Stock to provide for the exercise of the rights to purchase Common Stock as provided
for herein.

 

SECTION
5.

 

NO FRACTIONAL SHARES
OR SCRIP

 

No fractional shares or scrip representing fractional shares shall be issued upon the
exercise of this Agreement, but in lieu of such fractional shares the Company shall make a cash payment therefor upon the basis
of the then fair market value of one share of Common Stock.

 

SECTION
6.

 

NO RIGHTS AS STOCKHOLDER

 

This Agreement does not entitle the Warrantholder to any voting rights or other rights
as a stockholder of the Company prior to the exercise of this Agreement.

 

SECTION
7.

 

WARRANTHOLDER REGISTRY.

 

The Company shall maintain a registry showing the name and address of the registered
holder of this Agreement. Warrantholder’s initial address, for purposes of such registry, is set forth below Warrantholder’s
signature on this Agreement. Warrantholder may change such address by giving written notice of such changed address to the Company.

 

SECTION
8.

 

ADJUSTMENT RIGHTS

 

The Exercise Price and the number of shares of Common Stock purchasable hereunder are
subject to adjustment, as follows:

 

    	- 5 -

    	 

    

 

(a)          Merger Event. If
at any time there shall be Merger Event, then, as a part of such Merger Event, lawful provision shall be made so that the Warrantholder
shall thereafter be entitled to receive, upon exercise of this Agreement, the number of shares of common stock or other securities
or property (collectively, “Reference Property”) that the Warrantholder would have received in connection with
such Merger Event if Warrantholder had exercised this Agreement immediately prior to the Merger Event. In any such case, appropriate
adjustment (as determined in good faith by the Company’s Board of Directors) shall be made in the application of the provisions
of this Agreement with respect to the rights and interests of the Warrantholder after the Merger Event to the extent that the
provisions of this Agreement (including adjustments of the Exercise Price and adjustments to ensure that the provisions of this
Section 8 shall thereafter be applicable, as nearly as possible, to the purchase rights under this Agreement in relation to any
Reference Property thereafter acquirable upon exercise of such purchase rights) shall continue to be applicable in their entirety,
and to the greatest extent possible. Without limiting the foregoing, in connection with any Merger Event, upon the closing thereof,
the successor or surviving entity shall assume the obligations of this Agreement; provided that the foregoing assumption requirement
shall not apply if (i) the consideration to be paid for or in respect of the outstanding shares of Common Stock in such Merger
Event consists solely of cash and/or readily marketable securities, and (ii) the value of such consideration (as determined at
closing in accordance with the definitive executed transaction documents) to be paid for or in respect of each outstanding share
of Common Stock is at least three (3) times the Exercise Price in effect as of immediately prior to the closing of such Merger
Event. In connection with a Merger Event and upon Warrantholder’s written election to the Company, the Company shall cause
this Warrant Agreement to be exchanged for the consideration that Warrantholder would have received if Warrantholder had chosen
to exercise its right to have shares issued pursuant to the Net Issuance provisions of this Warrant Agreement without actually
exercising such right, acquiring such shares and exchanging such shares for such consideration. The provisions of this Section
8(a) shall similarly apply to successive Merger Events.

 

(b)          Reclassification of
Shares. Except for Merger Events subject to Section 8(a), and subject to Section 8(f), if the Company at any time shall, by
combination, reclassification, exchange or subdivision of securities or otherwise, change any of the securities as to which purchase
rights under this Agreement exist into the same or a different number of securities of any other class or classes, this Agreement
shall thereafter represent the right to acquire such number and kind of securities as would have been issuable as the result of
such change with respect to the securities which were subject to the purchase rights under this Agreement immediately prior to
such combination, reclassification, exchange, subdivision or other changer The provisions of this Section 8(b) shall similarly
apply to successive combination, reclassification, exchange, subdivision or other change.

 

(c)          Subdivision or Combination
of Shares. If the Company at any time shall combine or subdivide its Common Stock, (i) in the case of a subdivision, the Exercise
Price shall be proportionately decreased and the number of shares of Common Stock issuable hereunder shall be proportionately
increased, or (ii) in the case of a combination, the Exercise Price shall be proportionately increased and the number of shares
of Common Stock issuable hereunder shall be proportionately decreased.

 

(d)          Stock Dividends.
If the Company at any time while this Agreement is outstanding and unexpired shall:

 

(i)          pay a dividend
with respect to the Common Stock payable in Common Stock, then the Exercise Price shall be adjusted, from and after the date of
determination of stockholders entitled to receive such dividend or distribution, to that price determined by multiplying the Exercise
Price in effect immediately prior to such date of determination by a fraction (A) the numerator of which shall be the total number
of shares of Common Stock outstanding immediately prior to such dividend or distribution, and (B) the denominator of which shall
be the total number of shares of Common Stock outstanding immediately after such dividend or distribution; or

 

    	- 6 -

    	 

    

 

(ii)          make any other
distribution with respect to Common Stock (or stock into which the Common Stock is convertible), except any distribution specifically
provided for in any other clause of this Section 8, then, in each such case, provision shall be made by the Company such that
the Warrantholder shall receive upon exercise or conversion of this Warrant a proportionate share of any such distribution as
though it were the holder of the Common Stock (or other stock for which the Common Stock is convertible) as of the record date
fixed for the determination of the stockholders of the Company entitled to receive such distribution.

 

(e)          [Intentionally Deleted]

 

(f)          Notice of Adjustments.
If: (i) the Company shall declare any dividend or distribution upon its stock, whether in stock, cash, property or other securities;
(ii) there shall be any Merger Event; (iii) there shall be an Initial Public Offering; (iv) the Company shall sell, lease, license
or otherwise transfer all or substantially all of its assets; or (v) there shall be any voluntary dissolution, liquidation or
winding up of the Company; then, in connection with each such event, the Company shall send to the Warrantholder: (A) at least
ten (10) days’ prior written notice of the date on which the books of the Company shall close or a record shall be taken
for such dividend, distribution, subscription rights (specifying the date on which the holders of Common Stock shall be entitled
thereto) or for determining rights to vote in respect of such Merger Event, dissolution, liquidation or winding up; (B) in the
case of any such Merger Event, sale, lease, license or other transfer of all or substantially all assets, dissolution, liquidation
or winding up, at least ten (10) days’ prior written notice of the date when the same shall take place (and specifying the
date on which the holders of Common Stock shall be entitled to exchange their Common Stock for securities or other property deliverable
upon such Merger Event, dissolution, liquidation or winding up); and (C) in the case of an Initial Public Offering, the Company
shall give the Warrantholder at least ten (10) days’ written notice prior to the effective date thereof.

 

Each such written notice shall set forth, in reasonable detail, (i) the event requiring
the notice, and (ii) if any adjustment is required to be made, (A) the amount of such adjustment, (B) the method by which such
adjustment was calculated, (C) the adjusted Exercise Price (if the Exercise Price has been adjusted), and (D) the number of shares
subject to purchase hereunder after giving effect to such adjustment, and shall be given in accordance with Section 12(g) below.

 

(g)Timely Notice. Failure to timely provide such notice required by subsection
(f) above shall entitle Warrantholder to retain the benefit of the applicable notice period notwithstanding anything to the contrary
contained in any insufficient notice received by Warrantholder. For purposes of this subsection (g), and notwithstanding anything
to the contrary in Section 12(g), the notice period shall begin on the date Warrantholder actually receives a written notice containing
all the information required to be provided in such subsection (g).

 

    	- 7 -

    	 

    

 

SECTION
9.

 

REPRESENTATIONS, WARRANTIES
AND COVENANTS OF THE COMPANY

 

(a)          Reservation of Common
Stock. The Common Stock issuable upon exercise of the Warrantholder’s rights has been duly and validly reserved and,
when issued in accordance with the provisions of this Agreement, will be validly issued, fully paid and non-assessable, and will
be free of any taxes, liens, charges or encumbrances of any nature whatsoever (other than net income taxes imposed by law upon
the Warrantholder or consensual encumbrances entered into by the Warrantholder); provided, that the Common Stock issuable pursuant
to this Agreement may be subject to restrictions on transfer under state and/or federal securities laws. The Company has made
available to the Warrantholder true, correct and complete copies of its Charter and current bylaws. The issuance of certificates
for shares of Common Stock upon exercise of this Agreement shall be made without charge to the Warrantholder for any issuance
tax in respect thereof, or other cost incurred by the Company in connection with such exercise and the related issuance of shares
of Common Stock, except to the extent of net income taxes imposed by law upon the Warrantholder; provided, that the Company shall
not be required to pay any tax which may be payable in respect of any transfer and the issuance and delivery of any certificate
in a name other than that of the Warrantholder.

 

(b)          Due Authority.
The execution and delivery by the Company of this Agreement and the performance of all obligations of the Company hereunder, including
the issuance to Warrantholder of the right to acquire the shares of Common Stock, have been duly authorized by all necessary corporate
action on the part of the Company. This Agreement: (1) does not violate the Company’s Charter or current bylaws; (2) does
not contravene any law or governmental rule, regulation or order applicable to it; and (3) does not and will not contravene any
provision of, or constitute a default under, any indenture, mortgage, contract or other instrument to which it is a party or by
which it is bound. This Agreement constitutes a legal, valid and binding agreement of the Company, enforceable in accordance with
its terms, subject as to enforcement of remedies to applicable bankruptcy, insolvency, reorganization, moratorium or similar laws
affecting generally the enforcement of creditors’ rights and subject to a court’s discretionary authority with respect
to the granting of a decree ordering specific performance or other equitable remedies.

 

(c)          Consents and Approvals.
No consent or approval of, giving of notice to, registration with, or taking of any other action in respect of any state, federal
or other governmental authority or agency is required with respect to the execution, delivery and performance by the Company of
its obligations under this Agreement, except for the filing of notices pursuant to Regulation D under the Act and any filing required
by applicable state securities law (or an exemption therefrom), which filings will be effective by the time required thereby.

 

    	- 8 -

    	 

    

 

Issued Securities.   All issued and outstanding shares of Common
Stock or any other securities of the Company have been duly authorized and validly issued and are fully paid and nonassessable.
All outstanding shares of Common Stock and any other securities were issued in full compliance with all federal and state securities
laws. In addition, as of the date immediately preceding the date of this Agreement:

 

(i)          The authorized
capital of the Company consists of 150,000,000 shares of Common Stock, of which 95,216,587 shares are issued and outstanding.

 

(ii)          The Company
has reserved 9,035,016 shares of Common Stock for issuance under its Stock Option Plan(s), under which 9,035,016 options
are outstanding. Except as set forth on Schedule I attached hereto, there are no other options, warrants, conversion privileges
or other rights presently outstanding to purchase or otherwise acquire any authorized but unissued shares of the Company’s
capital stock or other securities of the Company. Except as set forth on Schedule II attached hereto, the Company has no outstanding
loans to any employee, officer or director of the Company.

 

(iii)        Other than in accordance
with the Company’s Charter, no stockholder of the Company has preemptive rights to purchase new issuances of the Company’s
capital stock.

 

(d)          [Intentionally Deleted]

 

(e)          Other Commitments to
Register Securities. Except as set forth in this Agreement or as set forth on Schedule III attached hereto, the Company is
not, pursuant to the terms of any other agreement currently in existence, under any obligation to register under the Act any of
its presently outstanding securities or any of its securities which may hereafter be issued.

 

(f)          Exempt Transaction.
Subject to the accuracy of the Warrantholder’s representations in Section 10, the issuance of the Common Stock upon exercise
of this Agreement will constitute a transaction exempt from (i) the registration requirements of Section 5 of the Act, in reliance
upon Section 4(2) thereof, and (ii) the qualification requirements of the applicable state securities laws.

 

(g)          Compliance with Rule
144. If the Warrantholder proposes to sell Common Stock issuable upon the exercise of this Agreement in compliance with Rule
144 promulgated by the SEC, then, upon Warrantholder’s written request to the Company, the Company shall furnish to the
Warrantholder, within ten days after receipt of such request, a written statement confirming the Company’s compliance with
the filing requirements of the SEC as set forth in such Rule, as such Rule may be amended from time to time.

 

(h)          Information Rights.
During the term of this Warrant, Warrantholder shall be entitled to the information rights contained in Section 7.1 of the Loan
Agreement, and Section 7.1 of the Loan Agreement is hereby incorporated into this Agreement by this reference as though fully
set forth herein, provided, however, that the Company shall not be required to deliver a Compliance Certificate once all Indebtedness
(as defined in the Loan Agreement) owed by the Company to Warrantholder has been repaid.

 

    	- 9 -

    	 

    

 

SECTION
10.

 

REPRESENTATIONS AND COVENANTS
OF THE WARRANTHOLDER

 

This Agreement has been entered into by the Company in reliance upon the following representations
and covenants of the Warrantholder:

 

(a)          Investment Purpose.
The acquisition of this Agreement and the right to acquire Common Stock is being acquired for investment purposes only, and not
with a view to the sale or distribution of any part thereof, and the Warrantholder has no present intention of selling or engaging
in any public distribution of such rights or the Common Stock, except pursuant to an effective registration statement or an exemption
from the registration requirements of the Act.

 

(b)          Private Issue.
The Warrantholder understands (i) that the Agreement and the Common Stock issuable upon exercise of this Agreement are not registered
under the Act or qualified under applicable state securities laws on the ground that the issuance contemplated by this Agreement
will be exempt from the registration and qualifications requirements thereof, and (ii) that the Company’s reliance on such
exemption is predicated on the representations set forth in this Section 10.

 

(c)          Financial Risk.
The Warrantholder has such knowledge and experience in financial and business matters as to be capable of evaluating the merits
and risks of its investment, and has the ability to bear the economic risks of its investment.

 

(d)          Investigation and Information.
The Warrantholder has been granted the opportunity to make a thorough investigation of the proposed activities of the Company,
has been furnished with all materials relating to the Company and its proposed activities that it has requested and has been afforded
the opportunity to obtain any additional information necessary to verify the accuracy of any representations made or information
conveyed to it. All questions posed and inquiries made by Warrantholder or its representative(s) concerning the Company and its
proposed business activities were answered to its satisfaction. In making its decision to invest in the Company, Warrantholder
has relied upon independent investigations made by Warrantholder and by his, her or its professional advisors. Warrantholder has
also been afforded the opportunity to obtain any additional nonproprietary information, to the extent the Company possesses that
information or can acquire it without unreasonable effort or expense, and has the right to furnish it to Warrantholder, necessary
to verify the accuracy of any representation or information contained in this Agreement.

 

(e)          Risk of No Registration.
The Warrantholder understands that if the Company does not register with the SEC pursuant to Section 12 of the Securities Exchange
Act of 1934 (the “1934 Act”), or file reports pursuant to Section 15(d) of the 1934 Act, or if a registration
statement covering the securities under the Act is not in effect when it desires to sell (i) the rights to purchase Common Stock
pursuant to this Agreement or (ii) the Common Stock issuable upon exercise of the right to purchase, it may be required to hold
such securities for an indefinite period. The Warrantholder also understands that any sale of (A) its rights hereunder to purchase
Common Stock, or (B) Common Stock issued or issuable hereunder, which might be made by it in reliance upon Rule 144 under the
Act may be made only in accordance with the terms and conditions of that Rule.

 

    	- 10 -

    	 

    

 

(f)          Accredited Investor.
Warrantholder is an “accredited investor” within the meaning of the Securities and Exchange Rule 501 of Regulation
D, as presently in effect.

 

(g)          Compliance with Securities
Act. Warrantholder, by acceptance hereof, agrees that this Agreement and the Common Stock (unless registered under the Act)
shall be stamped or imprinted with a legend in substantially the following form:

 

“THE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED, OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN
EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNSEL) REASONABLY SATISFACTORY
TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES
LAWS.”

 

(h)          Agreement in Connection
with Public Offering. In connection with the execution of this Agreement, the Warrantholder shall execute a lock up agreement
with the Company reasonably acceptable to the Company.

 

SECTION
11.

 

TRANSFERS

 

Subject to compliance with applicable federal and state securities laws, this Agreement
and all rights hereunder are transferable, in whole or in part, without charge to the holder hereof (except for transfer taxes)
upon surrender of this Agreement properly endorsed. Each taker and holder of this Agreement, by taking or holding the same, consents
and agrees that this Agreement, when endorsed in blank, shall be deemed negotiable, and that the holder hereof, when this Agreement
shall have been so endorsed and its transfer recorded on the Company’s books, shall be treated by the Company and all other
persons dealing with this Agreement as the absolute owner hereof for any purpose and as the person entitled to exercise the rights
represented by this Agreement. The transfer of this Agreement shalt be recorded on the books of the Company upon receipt by the
Company of a notice of transfer in the form attached hereto as Exhibit III (the “Transfer Notice”),
at its principal offices and the payment to the Company of all transfer taxes and other governmental charges imposed on such transfer.
Until the Company receives such Transfer Notice, the Company may treat the registered owner hereof as the owner for all purposes.

 

    	- 11 -

    	 

    

 

SECTION
12.

 

MISCELLANEOUS

 

(a)          Effective Date.
The provisions of this Agreement shall be construed and shall be given effect in all respects as if it had been executed and delivered
by the Company on the date hereof. This Agreement shall be binding upon any successors or assigns of the Company.

 

(b)          Remedies. In the
event of any default hereunder, the non-defaulting party may proceed to protect and enforce its rights either by suit in equity
and/or by action at law, including but not limited to an action for damages as a result of any such default, and/or an action
for specific performance for any default where Warrantholder will not have an adequate remedy at law and where damages will not
be readily ascertainable, The Company expressly agrees that it shall not oppose an application by the Warrantholder or any other
person entitled to the benefit of this Agreement requiring specific performance of any or all provisions hereof or enjoining the
Company from continuing to commit any such breach of this Agreement.

 

(c)          No Impairment of Rights.
The Company will not, by amendment of its Charter or through any other means, avoid or seek to avoid the observance or performance
of any of the terms of this Agreement, but will at all times in good faith assist in the carrying out of all such terms and in
the taking of all such actions as may be necessary or appropriate in order to protect the rights of the Warrantholder against
impairment.

 

(d)          Additional Documents.
The Company, upon execution of this Agreement, shall provide the Warrantholder with certified resolutions with respect to the
representations, warranties and covenants set forth in Sections 9(a) through 9(d), 9(f) and 9(g). The Company shall also supply
documentation reasonably necessary to evaluate whether to exercise (in cash or a net issuance basis) this Warrant, including without
limitation, (i) any merger/purchase/asset sale agreement and related documents and estimated payout allocations to each of the
respective stockholders, warrant and option holders in connection with a Merger Event, (ii) the most recent capitalization tables,
409A valuations (if any), and board determination of share value (including any waterfall or per share allocations provided to
the share/unitholders), and (iii) most recent articles of incorporation or organization (as applicable).

 

(e)          Attorney’s Fees.
In any litigation, arbitration or court proceeding between the Company and the Warrantholder relating hereto, the prevailing party
shall be entitled to reasonable attorneys’ fees and expenses and all costs of proceedings incurred in enforcing this Agreement.
For the purposes of this Section 12(e), attorneys’ fees shall include without limitation fees reasonably incurred in connection
with the following: (1) contempt proceedings; (ii) discovery; (iii) any motion, proceeding or other activity of any kind in connection
with an insolvency proceeding; (iv) garnishment, levy, and debtor and third party examinations; and (v) post-judgment motions
and proceedings of any kind, including without limitation any activity taken to collect or enforce any judgment.

 

(f)          Severability. In
the event any one or more of the provisions of this Agreement shall for any reason be held invalid, illegal or unenforceable,
the remaining provisions of this Agreement shall be unimpaired, and the invalid, illegal or unenforceable provision shall be replaced
by a mutually acceptable valid, legal and enforceable provision, which comes closest to the intention of the parties underlying
the invalid, illegal or unenforceable provision.

 

    	- 12 -

    	 

    

 

(g)          Notices. Except
as otherwise provided herein, any notice, demand, request, consent, approval, declaration, service of process or other communication
that is required, contemplated, or permitted under this Agreement or with respect to the subject matter hereof shall be in writing,
and shall be deemed to have been validly served, given, delivered, and received upon the earlier of: (i) the day of transmission
by facsimile or hand delivery if transmission or delivery occurs on a business day at or before 5:00 pm in the time zone of the
recipient, or, if transmission or delivery occurs on a non-business day or after such time, the first business day thereafter
or the first business day after deposit with an overnight express service or overnight mail delivery service; or (ii) the third
calendar day after deposit in the United States mails, with proper first class postage prepaid, and shall be addressed to the
party to be notified as follows:

 

If to Warrantholder:

 

STEWARD CAPITAL HOLDINGS, LP

Attention: Donald P. Johns, CFO

3900 S. Overland Avenue

Springfield, MO 65807 

Facsimile: 417-831-9998

Telephone: 417-520-2707

 

If to the Company:

 

CORINDUS VASCULAR ROBOTICS, INC.

Attention: David Long, Chief Financial Officer

309 Waverly Oaks Rd., Suite 105

Waltham, MA 02452

Facsimile: 805-653-3355

Telephone: 508-653-3335, Ext. 228

 

or to such other address as each party may designate for itself by like notice.

 

(h)          Amendment and Restatement
of Prior Warrant; Entire Agreement; Amendments. This Agreement amends and restates in its entirety the Prior Warrant. This
Agreement constitute the entire agreement and understanding of the parties hereto in respect of the subject matter hereof, and
supersede and replace in their entirety any prior proposals, term sheets, letters, negotiations or other documents or agreements,
whether written or oral, with respect to the subject matter hereof. None of the terms of this Agreement may be amended except
by an instrument executed by each of the parties hereto.

 

(i)          Headings. The various
headings in this Agreement are inserted for convenience only and shall not affect the meaning or interpretation of this Agreement
or any provisions hereof.

 

    	- 13 -

    	 

    

 

(j)          No Strict Construction.
The parties hereto have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question
of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto and no presumption
or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provisions of this Agreement.

 

(k)          No Waiver. No omission
or delay by Warrantholder at any time to enforce any right or remedy reserved to it, or to require performance of any of the terms,
covenants or provisions hereof by the Company at any time designated, shall be a waiver of any such right or remedy to which Warrantholder
is entitled, nor shall it in any way affect the right of Warrantholder to enforce such provisions thereafter.

 

(l)          Survival. All agreements,
representations and warranties contained in this Agreement or in any document delivered pursuant hereto shall be for the benefit
of Warrantholder and shall survive the execution and delivery of this Agreement and the expiration or other termination of this
Agreement.

 

(m)          Governing Law.
This Agreement has been negotiated and delivered to Warrantholder in the State of Missouri, and shall have been accepted by Warrantholder
in the State of Missouri. Delivery of Common Stock to Warrantholder by the Company under this Agreement is due in the State of
Missouri. This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of Missouri,
excluding conflict of laws principles that would cause the application of laws of any other jurisdiction.

 

(n)          Consent to Jurisdiction
and Venue. All judicial proceedings arising in or under or related to this Agreement may be brought in any state or federal
court of competent jurisdiction located in the State of Missouri. By execution and delivery of this Agreement, each party hereto
generally and unconditionally: (a) consents to personal jurisdiction in the State of Delaware; (b) waives any objection as to
jurisdiction or venue in the State of Delaware; (c) agrees not to assert any defense based on lack of jurisdiction or venue in
the aforesaid courts; and (d) irrevocably agrees to be bound by any judgment rendered thereby in connection with this Agreement.
Service of process on any party hereto in any action arising out of or relating to this Agreement shall be effective if given
in accordance with the requirements for notice set forth in Section 12(g), and shall be deemed effective and received as set forth
in Section 12(g). Nothing herein shall affect the right to serve process in any other manner permitted by law or shall limit the
right of either party to bring proceedings in the courts of any other jurisdiction.

 

(o)          Mutual Waiver of Jury
Trial. Because disputes arising in connection with complex financial transactions are most quickly and economically resolved
by an experienced and expert person and the parties wish applicable state and federal laws to apply (rather than arbitration rules),
the parties desire that their disputes be resolved by a judge applying such applicable laws. EACH OF THE COMPANY AND WARRANTHOLDER
SPECIFICALLY WAIVES ANY RIGHT IT MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY
CLAIM OR ANY OTHER CLAIM WITH RESPECT TO THIS AGREEMENT (COLLECTIVELY, “CLAIMS”) ASSERTED BY THE COMPANY AGAINST WARRANTHOLDER
OR ITS ASSIGNEE OR BY WARRANTHOLDER OR ITS ASSIGNEE AGAINST THE COMPANY. This waiver extends to all such Claims, including Claims
that involve Persons other than Company and Warrantholder; Claims that arise out of or are in any way connected to the relationship
between the Company and Warrantholder; and any Claims for damages, breach of contract, specific performance, or any equitable
or legal relief of any kind, arising out of this Agreement.

 

    	- 14 -

    	 

    

 

(p)          Prejudgment Relief.
In the event Claims are to be resolved by arbitration, either party may seek from a court of competent jurisdiction identified
in Section 12(n), any prejudgment order, writ or other relief and have such prejudgment order, writ or other relief enforced to
the fullest extent permitted by law notwithstanding that all Claims are otherwise subject to resolution by judicial reference.

 

(q)          Counterparts. This
Agreement and any amendments, waivers, consents or supplements hereto may be executed in any number of counterparts, and by different
parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts
shall constitute but one and the same instrument.

 

(r)          Loan Agreement.
This Agreement is the “Warrant” issued pursuant to the Loan Agreement.

 

[Remainder of Page Intentionally Left Blank]

 

    	- 15 -

    	 

    

 

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by its
officers thereunto duly authorized as of the Effective Date.

 

	COMPANY:	CORINDUS VASCULAR ROBOTICS, INC.
	 	 
	 	By:	/s/ David M. Handler
	 	Name: 	David M. Handler
	 	Title:	Chief Executive Officer
	 	 	 
		STEWARD CAPITAL HOLDINGS, LP
	WARRANTHOLDER:	 	 
	 	By:	/s/ Donald P. Johns
	 	Name:	Donald P. Johns
	 	Title:	Vice President/CFO

 

    	- 16 -

    	 

    

 

EXHIBIT I

 

NOTICE OF EXERCISE

 

		To:	CORINDUS VASCULAR ROBOTICS, INC.

 

	(1)	The undersigned Warrantholder hereby elects to purchase [_________] shares of the Common
                                 Stock of Corindus Vascular Robotics, Inc., pursuant to the terms of the Agreement dated the [___]
                                 day of June, 2014 (the “Agreement”) between Corindus Vascular Robotics, Inc. and
                                 the Warrantholder, and [CASH PAYMENT; tenders herewith payment of the Purchase Price in full,
                                 together with all applicable transfer taxes, if any.] [NET ISSUANCE: elects pursuant to Section
                                 3(a) of the Agreement to effect a Net Issuance.]
	 	 
	(2)	Please issue a certificate or certificates representing said shares of Common Stock in the name of the undersigned
            or in such other name as is specified below.
	 	 
	(3)	The undersigned Warrantholder hereby represents that it is acquiring such shares for its own account, for investment
            purposes only, and not with a view to, or for sale in connection with, any distribution of any part thereof. The undersigned
            further represents and confirms that the representations and warranties of the Warrantholder set forth in Section
            10 of the attached Agreement are true and correct as of the date hereof.

 

	 	(Name)	 
	 	 	 
	 	(Address)	 
	 	 	 
	WARRANTHOLDER:	 	 

 

    	- 17 -

    	 

    

 

EXHIBIT II

 

ACKNOWLEDGMENT OF EXERCISE

 

The undersigned officer of Corindus Vascular Robotics, Inc. hereby acknowledges receipt
of the “Notice of Exercise” from [Warrantholder] to purchase [_____] shares of the Common Stock of Corindus Vascular
Robotics, Inc., pursuant to the terms of the Agreement, and further acknowledges that [_____] shares remain subject to purchase
under the terms of the Agreement.

 

	COMPANY:	CORINDUS VASCULAR ROBOTICS, INC.
	 	 
	 	By:	 
	 	Name:	 
	 	Title:	 

 

    	- 18 -

    	 

    

 

EXHIBIT III

 

TRANSFER NOTICE

 

(To transfer or assign the foregoing Agreement execute this form and supply required
information. Do not use this form to purchase shares.)

 

FOR VALUE RECEIVED, the foregoing Agreement and all rights evidenced thereby are hereby
transferred and assigned to

 

	 
	(Please Print)		 	 
	 	 	 	 
	whose address is	 
	 
	 
	 	 	 	 
	 	 	Dated:	 
	 	 	 	 
	 	 	Holder’s Signature:	 
	 	 	 	 
	 	 	Holders Address:	 

 

	Signature Guaranteed:	 

 

NOTE: The signature to this Transfer Notice must correspond with the name as it appears
on the face of the Agreement, without alteration or enlargement or any change whatever. Officers of corporations and those acting
in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Agreement.

 

    	- 19 -

    	 

    

 

SCHEDULE I

 

OPTIONS AND WARRANTS

 

    	- 20 -

    	 

    

 

SCHEDULE II

 

LOANS

 

    	- 21 -

    	 

    

 

SCHEDULE III

 

REGISTRATION RIGHTS

 

- 22 -Your Internet Defender, Inc. 8-K/A

Exhibit 10.24

 

Warrant

 

To: NARKIS GRYP Ltd. (the “Holder”)

 

Date: August 12, 2014

 

WARRANT

 

to Purchase Common Stock

(“Common Stock”)

of Corindus Vascular Robotics, Inc.

Subject to the terms and conditions set forth
below

VOID AFTER 24:00 p.m. Eastern Time

On the last day of the Warrant Period (defined
below).

(issued in replacement of the Warrant issued
October 11, 2010)

 

WHEREAS, Corindus, Inc.,
(the “Predecessor Company”) issued to the Holder that certain Warrant to Purchase Series A Preferred Stock,
dated October 11, 2010 (the “Prior Warrant”);

 

WHEREAS, the Predecessor
Company and Corindus Vascular Robotics, Inc. (the “Company”) entered into a Securities Exchange and Acquisition
Agreement dated August 5, 2014 whereby the Company agreed to acquire 100% of the issued and outstanding shares of common stock
and preferred stock of the Predecessor Company and rights to acquire shares of common stock and preferred stock of the Predecessor
Company, including the Prior Warrant, through an acquisition in exchange for the issuance of shares and rights to acquire shares
of the Company’s Common Stock; and

 

WHEREAS, the Company and
the Holder desire to amend and restate the Prior Warrant as set forth in this Warrant to reflect the right to purchase shares
of Common Stock of the Company.

 

NOW, THEREFORE, the parties hereby
agree as follows:

 

This is to certify that
the Holder is entitled to purchase, subject to the provisions of this Warrant, from the Company, at any time from the date hereof,
and terminating upon May 31, 2017 (the “Warrant Period”), up to 124,160 fully paid and non-assessable shares
of Common Stock, par value of $0.0001 per share (the “Warrant Shares” or “Shares”) of the
Company at an exercise price of USD$0.7648 per Warrant Share, all subject to adjustments for anti-dilution, sub-division, split,
combination or recapitalization, pursuant to the Certificate of Incorporation of the Company, as amended from time to time (the
“Exercise Price”, and “Certificate”, respectively). This Warrant is issued in substitution
of and replacement for the Prior Warrant.

 

    	 

    	 

    

 

	1.	Exercise of Warrant

 

		1.1	Exercise. Subject to the provisions hereof, this Warrant may
be exercised, in whole or in part, on one or more occasions at any time during the Warrant Period. Notice of exercise of this Warrant
(i) in connection with an IPO (as defined below), may be made conditional upon closing of such public offering, (ii) in connection
with a Sale (as defined below), may be made conditional upon closing of such Sale, (iii) in connection with a Merger (as defined
below), may be made conditional upon closing of such Merger, and (iv) in connection with a Distribution (as defined below), may
be made conditional upon completion of such Distribution.

 

The term “IPO”
means an initial public offering of the shares of the Company.

 

The term “Sale”
means the sale of all or substantially all of the assets of the Company.

 

The term “Merger”
means a merger in which the shareholders of the Company, immediately after the merger, do not own a majority of the outstanding
shares of the surviving corporation.

 

The term “Distribution”
means distribution of cash dividend.

 

		1.2	Exercise for Cash. This Warrant shall be exercised by presentation
and surrender hereof at the principal office of the Company, accompanied by (i) a written notice of exercise, and (ii) payment
to the Company, for the account of the Company, of the Exercise Price for the number of Warrant Shares specified in such notice.
The Exercise Price for the number of Warrant Shares specified in the notice shall be available in good funds, in U.S. dollars.

 

		1.3	Exercise on Net Issuance Basis. In lieu of cash payment to
the Company as set forth in Section 1.2 above, the Holder may convert this Warrant (“Conversion Right”) in whole
or in part into the number of shares of Common Stock of the Company each calculated pursuant to the following formula, by surrendering
this Warrant to the Company at the principal office of the Company, accompanied by a written notice of exercise, specifying the
number of shares of Common Stock into which the Holder desires to convert this Warrant (namely, the number of shares of Common
Stock obtainable upon conversion of the Warrant Shares to which the Holder is entitled upon exercise of this Warrant):

 

	X =	Y (A
- B)
	A

  

wherein –

 

Xequals the
number of shares of Common Stock to be issued to the Holder;

 

Yequals the
number of shares of Common Stock obtainable upon conversion of the Warrant Shares to which the Holder is entitled upon exercise
of this Warrant (as adjusted to the date of such calculation, but excluding those shares already issued under this Warrant);

 

Bequals the
Exercise Price in effect at the time of exercise pursuant to this formula; and

 

    	2

    	 

    

 

Aequals
the fair market value of one share of Common Stock of the Company.

 

Fair market
value shall be determined as follows:

 

With reference
to the exercise of this Warrant, in whole or in part, in connection with the IPO, fair market value shall mean the price to the
public in the IPO of one share of Common Stock, less the underwriter’s commission;

 

With reference
to the exercise of this Warrant, in whole or in part, in connection with a Sale or a Merger, the fair market value of a share of
Common Stock shall be as calculated by the auditors of the Company, based on the total consideration to be received by the Company
(for its stock or assets, as the case may be), taking into account the number of shares calculated on a fully diluted basis (including
the Warrant Shares to be issued pursuant to this Warrant), and taking into account the rights attached to the Warrant Shares pursuant
to the Certificate.

 

If the Common
Stock of the Company is traded on a securities exchange or through the Nasdaq National Market, the fair market value shall be deemed
to be the average of the closing prices of the securities on such quotation system over the thirty (30) day period ending three
(3) days prior to the date of the exercise notice.

 

If there is
no active public market, the fair market value shall be as determined by an independent public accountant retained by the Holder
in consultation with the Board of Directors of the Company.

 

		1.4	Partial Exercise, Etc. If this Warrant should be exercised
in part only, the Company shall, upon surrender of this Warrant for cancellation, execute and deliver a new Warrant evidencing
the rights of the Holder to purchase the balance of the shares purchasable hereunder.

 

		1.5	Issuance of the Warrant Shares. Upon presentation and surrender
of the notice of exercise accompanied by the payment of the Exercise Price (if applicable) pursuant to Section 1.2 or Section 1.3,
the Company shall issue promptly to the Holder the shares to which the Holder is entitled thereto, duly authorized, validly issued,
fully paid, non-assessable and free and clear of all liens, pledges, security interests, charges, encumbrances, equities or claims
and not subject to any preemptive rights and/or restrictions on sale or transfer. Upon receipt by the Company of the notice of
exercise (and the Exercise Price, if applicable), the Holder shall be deemed to be the Holder of the shares issuable upon such
exercise, notwithstanding that the share transfer books of the Company shall then be closed and that certificates representing
such shares shall not then be actually delivered to the Holder. The Company shall pay all taxes (including stamp duty) and other
charges that may be payable in connection with the issuance of this Warrant and with the issuance of the Warrant Shares and the
preparation and delivery of share certificates pursuant to this Section 1 in the name of the Holder, but shall not pay any taxes
payable by the Holder by virtue of the holding, issuance, exercise or sale of this Warrant by the Holder.

 

    	3

    	 

    

 

No fractions
of Shares shall be issued in connection with the exercise of this Warrant, and the number of Shares issued shall be rounded down
to the nearest whole number.

 

	2.	Reservation of Shares: Preservation of Rights of Holder

 

The Company hereby
agrees that at all times it will maintain and reserve, free from preemptive rights, such number of authorized but unissued Warrant
Shares so that this Warrant may be exercised without additional authorization of Warrant Shares after giving effect to all other
options, warrants, convertible securities and other rights to acquire shares of the Company. The Company further agrees that it
will not, by amendment of its Certificate or through reorganization, consolidation, merger, dissolution or sale of assets, or by
any other voluntary act, avoid or seek to avoid the observance or performance of any of the covenants, stipulations or conditions
to be observed or performed buyer by the Company, or the provisions contained in the Certificate relating to the rights of the
holders of the Warrant Shares.

 

		3.	Adjustment

 

The number of
Shares purchasable upon the exercise of this Warrant and the Exercise Price shall be subject to adjustment from time to time or
upon exercise as provided in this Section 3 if any of the mentioned below occurs prior to the end of the Warrant Period:

 

		3.1	Rights Offer: If the Company’s stockholders are offered any securities whatsoever
by a rights issue, neither the Exercise Price nor the quantity of Warrant Shares will be adjusted, provided that the Company shall
offer identical rights on the same terms and conditions to the Holder, as if the Holder had exercised this Warrant in full immediately
prior to the date of conferring the right to participate in the rights issue.

 

		3.2	Consolidation and Division: If the Company consolidates any securities as to which
purchase rights exist under this Warrant into shares of greater nominal value, or subdivides them into shares of lesser nominal
value, the number of Warrant Shares to be allotted on exercise of this Warrant after such consolidation or subdivision will be
reduced or increased, as the case may be, such increase or decrease, as the case may be, to become effective immediately after
the opening of business on the day following the day upon which such subdivision or consolidation becomes effective, and in each
case the Exercise Price shall be adjusted appropriately. The Holder will not be entitled to receive a fraction of a Warrant Share.

 

		3.3	Bonus Shares: In the event of a distribution of bonus shares, this Warrant shall
represent the right to acquire, in addition to the number of Warrant Shares indicated in the caption of this Warrant, and without
payment of any additional consideration therefor, the amount of such bonus shares to which the Holder hereof would have been entitled
had this Warrant been exercised prior to the distribution of the bonus shares.

 

    	4

    	 

    

 

		3.4	Merger or Reorganization etc: If at any time while this Warrant, or any portion thereof,
is outstanding and unexpired there shall be (i) a reorganization (other than a consolidation, reclassification, exchange or subdivision
of shares otherwise provided for herein), (ii) a merger or consolidation of the Company with or into another corporation in which
the Company is not the surviving entity, or a merger in which the Company is the surviving entity but the issued and outstanding
share capital of the Company’s immediately prior to the merger are converted by virtue of the merger into the property, whether
in the form of securities, cash, or otherwise, or (iii) a sale or transfer of the Company’s properties and assets as, or
substantially as, an entirety to any other person; then, as a part of such reorganization, merger, consolidation, sale or transfer,
lawful provision shall be made so that the holder of this Warrant shall thereafter be entitled to receive upon exercise of this
Warrant, during the period specified herein and upon payment of the Exercise Price then in effect (subject to Section 1.3), the
number of shares or other securities or property of the successor corporation resulting from such reorganization, merger, consolidation,
sale or transfer that a holder of the shares deliverable upon exercise of this Warrant would have been entitled to receive in such
reorganization, consolidation, merger, sale or transfer if this Warrant had been exercised immediately before such reorganization,
merger, consolidation, sale or transfer, all subject to further adjustment as provided in this Section. If the per-share consideration
payable to the Holder hereof for shares in connection with any such transaction is in a form other than cash or marketable securities,
then the value of such consideration shall be determined in good faith by the Company’s auditors.

 

Upon the occurrence
of any transaction referred to in Section 5 of the Amended and Restated Voting Agreement dated November 18, 2009 between the
Predecessor Company and the various entities party thereto (the “Voting Agreement”), the Board of Directors
of the Company may issue to the Holder hereof a 30 day written notice under which the Warrant shall expire if not exercised immediately
prior to the closing of such transaction and subject to the consummation of said transaction. To avoid any doubt, shares acquired
as a result of the exercise of the Warrant shall become part of the Sale of the Company (as defined in the Voting Agreement).

 

		3.5	Cash Dividend: In the event of a Distribution, the Exercise Price would be reduced
by the full amount of the cash dividend per share. If due to such a Distribution the Exercise Price is expected to be reduced to
zero, the Holder shall be granted prior written notice, no less than fifteen (15) days prior to the Distribution, describing the
terms of the Distribution. Notice of exercise of this Warrant in connection with the Distribution may be conditional upon actual
completion of such Distribution to the shareholders as per the Company’s notice, in which event the Holder shall not be deemed
to have exercised the Warrant until immediately prior to the Distribution. The amount of the Distribution per share to Holder shall
be equal to the amount of the cash dividend per share minus the Exercise Price (prior to the adjustment hereof).

 

    	5

    	 

    

 

		3.6	Exercise Price: Upon any adjustment in the number of Warrant Shares purchasable hereunder,
the Exercise Price shall be proportionately increased or decreased, as the case may be, in a manner that is the inverse of the
manner in which the number of Warrant Shares purchasable hereunder shall be adjusted.

 

		3.7	Notices: Whenever the number of Warrant Shares for which this Warrant is exercisable,
is adjusted as provided in this Section 2, the Company shall promptly compute such adjustment and mail to the Holder at the last
address provided to the Company in writing, a certificate signed by a principal financial officer of the Company, setting forth
the number of Warrant Shares for which this Warrant is exercisable and the Exercise Price as a result of such adjustment, a brief
statement of the facts requiring such adjustment and the computation thereof and when such adjustment has or will become effective.

 

	4.	Exchange or Loss of Warrant

 

Upon receipt
by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant, and (in
the case of loss, theft or destruction) of reasonably satisfactory indemnification, and upon surrender and cancellation of this
Warrant, if mutilated, the Company will execute and deliver a new Warrant of like tenor and date. Any such new Warrant executed
and delivered shall constitute an additional contractual obligation on the part of the Company, whether or not the Warrant so lost,
stolen, destroyed or mutilated, shall be at any time enforceable by anyone.

 

	5.	Share Swap

 

The Company
undertakes not to enter into any share swap agreement or arrangement (such as a merger, reorganization, or sale of all, or substantially
all, of the Company’s shares) (“Share Swap”), unless the other Company to such a Share Swap agreement
undertakes to allot to the Holder, upon, and subject to, the exercise of this Warrant, such securities as were swapped for the
shares of the Company, as though the Holder had held the Warrant Shares on the record date of the Share Swap.

 

	6.	Rights of the Holder

 

		6.1	Without limiting the foregoing or any remedies available to the Holder,
the Holder will be entitled to specific performance of the obligations hereunder and injunctive relief against actual or threatened
violations of the obligations of any person subject to this Warrant.

 

		6.2	The Holder shall not, by virtue hereof, and except as provided herein, be
entitled to any rights of a shareholder in the Company, until and to the extent the Warrant shall have been exercised as provided
herein.

 

    	6

    	 

    

 

	7.	[Intentionally
Deleted]

 

	8.	Transfer of Warrant 

 

		8.1	This Warrant may not be sold, transferred, assigned or hypothecated by the
Holder.

 

		8.2	The terms and provisions of this warrant shall inure to the benefit of,
and be binding upon, the Company and the Holder hereof and their respective successors and assigns.

 

	9.	Representations and Warranties

 

The Company represents
and warrants to the Holder as follows:

 

		9.1	This Warrant has been duly authorized and executed by the Company and is a valid and binding obligation
of the Company enforceable in accordance with its terms.

 

		9.2	The execution and delivery of this Warrant are not, and the issuance of the Shares upon exercise
of the Warrant in accordance with the terms hereof, will not be inconsistent with the Certificate, do not and will not contravene
any law, governmental rule or regulation, judgment or order applicable to the Company and, except for the consents already obtained
by the Company, do not and will not conflict with or contravene any provisions of, or constitute a default under, any indenture,
mortgage, contract or other instrument to which the Company is a party or by which it is bound or require the consent or approval
of, the giving the notice to, the registration with or taking of any action in respect of or by any governmental authority.

 

		9.3	The Company covenants and agrees that all shares which may be issued upon the exercise of the Warrant
evidenced hereby will be duly authorized, validly issued, fully paid and non-assessable (subject to payment of the Exercise Price
thereof, if applicable). The Company shall at all times reserve and keep available for issuance upon the exercise of the Warrant,
such number of its authorized but un-issued shares as will from time to time be sufficient to permit the exercise of all outstanding
Warrants.

 

	10.	Termination 

 

This Warrant and
the rights conferred hereby shall terminate at the aforementioned time on the last day of the Warrant Period.

 

    	7

    	 

    

 

	11.	Governing Law

 

This Warrant
shall be governed by, and interpreted in accordance with, the laws of the State of Delaware, without giving effect to the rules
respecting conflict of law.

 

	12.	Notices

 

Unless otherwise
provided, any notice required or permitted under this Warrant shall be given in writing, with a duplicate copy sent via email and
shall be deemed effectively given upon personal delivery to the party to be notified or 7 (seven) days after deposit with a Post
Office, for dispatch by registered or certified mail, postage prepaid and addressed to the Holder at the address set forth in the
Company’s books and to the Company at the address of its principal offices. With respect to Holders located outside Israel,
such notice shall be deemed effectively given upon personal delivery to the party to be notified, 10 (ten) business days after
deposit with a Post Office for dispatch by registered or certified airmail, or when given by telex, telecopier, facsimile or other
form of rapid written communication, the day sent, provided that confirming copies are sent by such airmail.

 

	13.	Amendment and Restatement of Prior Warrant; Amendments

 

This Warrant
amends and restates in its entirety the Prior Warrant. Any term of this Warrant may only be amended with the written consent of
(i) the Company and (ii) the Holder.

 

	DATED: August 12, 2014	Corindus Vascular Robotics, Inc.
	 	 	 
	 	By: 	/s/ David M. Handler
	 	Name:  	David M. Handler
	 	Title:	Chief Executive Officer
	 	 	 
	DATED: August 12, 2014	NARKIS GRYP Ltd.
	 	 	 
	 	By:	/s/ Dalia Prashkar
	 	Name:	Dalia Prashkar
	 	Title:	Owner

 

8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}]]